Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Corcept Therapeutics
Study ID
NCT02762981
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.

Key Dates

First listed
May 5, 2016
Start date
May 23, 2016
Status verified
Nov 2022
Primary completion
May 12, 2020
Completion
Sep 12, 2020

Study Design

Enrollment
85 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Relacorilant with nab-paclitaxel
    Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.

Primary Outcome Measure

Number of Participants With Dose-limiting Toxicity [ Time Frame: Up to completion of Cycle 1 (up to 28 days) ]

Locations (4)

FacilityCityStateZIPSite coordinators
038ScottsdaleArizona85258-
014San FranciscoCalifornia94143-
001ChicagoIllinois60637-
013OgdenUtah84403-

Find similar trials in Scottsdale, AZ

By research site
038· Scottsdale, AZ014· San Francisco, CA001· Chicago, IL013· Ogden, UT

Related Studies